Home » Stocks » Clovis Oncology

Clovis Oncology, Inc. (CLVS)

Stock Price: $5.72 USD 0.00 (0.00%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $5.77 +0.05 (0.87%) Oct 20, 7:50 PM

Stock Price Chart

Key Info

Market Cap 504.52M
Revenue (ttm) 159.36M
Net Income (ttm) -385.16M
Shares Out 88.20M
EPS (ttm) -5.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $5.72
Previous Close $5.72
Change ($) 0.00
Change (%) 0.00%
Day's Open 5.71
Day's Range 5.50 - 5.88
Day's Volume 3,447,911
52-Week Range 2.93 - 17.37

More Stats

Market Cap 504.52M
Enterprise Value 859.04M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 88.20M
Float 85.66M
EPS (basic) -6.07
EPS (diluted) -5.89
FCF / Share -3.37
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 39.17M
Short Ratio 7.35
Short % of Float 45.72%
Beta 2.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.17
PB Ratio n/a
Revenue 159.36M
Operating Income -362.75M
Net Income -385.16M
Free Cash Flow -271.08M
Net Cash -354.52M
Net Cash / Share -4.02
Gross Margin 70.96%
Operating Margin -227.63%
Profit Margin -241.70%
FCF Margin -170.11%
ROA -33.61%
ROE -547.55%
ROIC -40.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 1
Overweight 0
Hold 3
Underweight 1
Sell 2

Analyst Consensus: Hold

Price Target

(51.57% upside)
Current: $5.72
Target: 8.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth49.92%71.84%71067.95%-------
Gross Profit10873.3143.770.01-13.63----
Operating Income-377-334-238-398-401-158-83.36-73.78-54.59-38.63
Net Income-400-368-346-349-353-160-84.53-73.98-55.57-37.83
Shares Outstanding53.8752.0747.0538.4836.0333.8928.6724.923.851.33
Earnings Per Share-7.43-7.07-7.36-9.07-9.79-4.72-2.95-2.97-14.42-28.55
Operating Cash Flow-324-366-261-267-253-117-71.71-65.38-39.83-34.01
Capital Expenditures-3.02-9.24-3.00-0.70-3.04-2.29-0.12-1.06-0.45-0.77
Free Cash Flow-327-375-264-267-256-119-71.83-66.44-40.27-34.78
Cash & Equivalents29752056426652948332314414022.30
Total Debt715575282281280279----
Net Cash / Debt-418-55.32281-14.9424920432314414022.30
Book Value-174146368-3.63301332498133132-54.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Clovis Oncology, Inc.
Country United States
Employees 484
CEO Patrick J. Mahaffy

Stock Information

Ticker Symbol CLVS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLVS
IPO Date November 16, 2011


Clovis Oncology, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.